Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Chronic Heart Failure

  Free Subscription


12.07.2021

1 Cardiovasc Res
2 Circ Heart Fail
1 Clin Cardiol
1 Eur Heart J
47 Eur J Heart Fail
1 Hypertension
1 J Card Fail
1 J Cardiovasc Pharmacol
1 J Thorac Cardiovasc Surg
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Cardiovasc Res

  1. GRASSI G, Mancia G, Esler M
    CENTRAL AND PERIPHERAL SYMPATHETIC ACTIVATION IN HEART FAILURE.
    Cardiovasc Res. 2021 Jul 7. pii: 6317668. doi: 10.1093.
    PubMed         Abstract available


    Circ Heart Fail

  2. DALLA ZUANNA T, Cacciani L, Barbieri G, Batzella E, et al
    Avoidable Hospitalization for Heart Failure Among a Cohort of 18- to 64-Year-Old Italian Citizens and Immigrants: Results From the Italian Network for Longitudinal Metropolitan Studies.
    Circ Heart Fail. 2021 Jul 8:CIRCHEARTFAILURE120008022.
    PubMed         Abstract available

  3. KHAN MS, Sreenivasan J, Shahid I, Bhinder J, et al
    Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States.
    Circ Heart Fail. 2021 Jul 8:CIRCHEARTFAILURE120008147.
    PubMed        


    Clin Cardiol

  4. ZHANG D, Lai W, Liu X, Shen Y, et al
    The safety of morphine in patients with acute heart failure: A systematic review and meta-analysis.
    Clin Cardiol. 2021 Jul 8. doi: 10.1002/clc.23691.
    PubMed         Abstract available


    Eur Heart J


  5. European Heart Journal Team Heart Failure.
    Eur Heart J. 2021 Jul 5. pii: 6314555. doi: 10.1093.
    PubMed        


    Eur J Heart Fail

  6. FARMAKIS D, Filippatos G
    Arrhythmias in cancer: rhythm is gonna get you!
    Eur J Heart Fail. 2021;23:154-156.
    PubMed        

  7. ANKER MS, von Haehling S, Coats AJS, Riess H, et al
    Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study.
    Eur J Heart Fail. 2021;23:145-153.
    PubMed         Abstract available

  8. RAPEZZI C, Giannini F, Campo G
    Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle?
    Eur J Heart Fail. 2021;23:259-263.
    PubMed        

  9. STEWART S, Playford D, Scalia GM, Currie P, et al
    Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.
    Eur J Heart Fail. 2021;23:406-416.
    PubMed         Abstract available

  10. BONDERMAN D
    How to ATTR-ACT the perfect match?
    Eur J Heart Fail. 2021;23:275-276.
    PubMed        

  11. HAZEBROEK MR, Henkens MTHM, Raafs AG, Verdonschot JAJ, et al
    Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial.
    Eur J Heart Fail. 2021;23:302-309.
    PubMed         Abstract available

  12. MULLENS W, Martens P
    Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic.
    Eur J Heart Fail. 2021;23:79-82.
    PubMed        

  13. ASLEH R, Amir O, Kushwaha SS
    Dynamics of myocardial fibrosis after left ventricular assist device implantation: should speeding up the scar have us scared stiff?
    Eur J Heart Fail. 2021;23:335-338.
    PubMed        

  14. LOARDI C, Zanobini M
    Aortic valve surgery and left ventricular assist device: lights and shadows. Letter regarding the article 'Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an ISHLT Mechanically Assisted Circulator
    Eur J Heart Fail. 2021;23:841-842.
    PubMed        

  15. RAPEZZI C, Aimo A, Emdin M
    Tafamidis is entering the clinical arena for the treatment of transthyretin-related cardiomyopathy: certainties and unmet needs.
    Eur J Heart Fail. 2021;23:286-289.
    PubMed        

  16. CHESSA M, Tutarel O
    Adults with congenital heart disease - we need more Europe for a better care.
    Eur J Heart Fail. 2021;23:454-455.
    PubMed        

  17. DOBNER S
    Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
    Eur J Heart Fail. 2021;23:681-682.
    PubMed        

  18. BRIDA M, Simkova I, Jovovic L, Prokselj K, et al
    European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required.
    Eur J Heart Fail. 2021;23:445-453.
    PubMed         Abstract available

  19. CHIONCEL O, Collins SP, Seferovic P
    Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply.
    Eur J Heart Fail. 2021;23:197-198.
    PubMed        

  20. SINAGRA G, Porcari A, Gentile P, Artico J, et al
    Viral presence-guided immunomodulation in lymphocytic myocarditis: an update.
    Eur J Heart Fail. 2021;23:211-216.
    PubMed         Abstract available

  21. ROSENBLUM H, Masri A, Narotsky DL, Goldsmith J, et al
    Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:250-258.
    PubMed         Abstract available

  22. ITO M, Matsue Y, Minamino T
    Worsening renal function during intensive blood pressure control: another example of not prognostically relevant creatinine rise?
    Eur J Heart Fail. 2021;23:393-395.
    PubMed        

  23. HAGNAS MJ, Grasso C, Di Salvo ME, Sardone A, et al
    Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair.
    Eur J Heart Fail. 2021;23:677-679.
    PubMed        

  24. NICOL M, Deney A, Lairez O, Vergaro G, et al
    Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:231-239.
    PubMed         Abstract available

  25. SANDERS-VAN WIJK S, Barandiaran Aizpurua A, Brunner-La Rocca HP, Henkens MTHM, et al
    The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2021;23:838-840.
    PubMed        

  26. DAMY T, Garcia-Pavia P, Hanna M, Judge DP, et al
    Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Eur J Heart Fail. 2021;23:277-285.
    PubMed         Abstract available

  27. BEZARD M, Kharoubi M, Galat A, Poullot E, et al
    Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis.
    Eur J Heart Fail. 2021;23:264-274.
    PubMed         Abstract available

  28. SPERRY BW, Tang Y, Jones PG, Spertus JA, et al
    Cumulative events in the TOPCAT trial.
    Eur J Heart Fail. 2021;23:491-492.
    PubMed        

  29. BHATT AS, Yanamandala M, Konstam MA
    For vaptans, as for life, balance is better.
    Eur J Heart Fail. 2021;23:751-753.
    PubMed        

  30. LYLE MA, Cooper LT
    Failure of intravenous immunoglobulin to improve cardiac function in parvovirus B19-associated chronic dilated cardiomyopathy.
    Eur J Heart Fail. 2021;23:310-311.
    PubMed        

  31. PERLINI S, Mussinelli R, Salinaro F
    New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:290-292.
    PubMed        

  32. CASTIGLIONE V, Franzini M, Aimo A, Carecci A, et al
    Use of biomarkers to diagnose and manage cardiac amyloidosis.
    Eur J Heart Fail. 2021;23:217-230.
    PubMed         Abstract available

  33. BOUDOULAS KD, Boudoulas H
    Time and left ventricular function: the forgotten dynamic factor.
    Eur J Heart Fail. 2021;23:552-554.
    PubMed        

  34. PAGNESI M, Adamo M, Metra M
    February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy.
    Eur J Heart Fail. 2021;23:201-202.
    PubMed        

  35. MULLENS W, Martens P, Witte K, Cowie MR, et al
    Reply to 'Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy'.
    Eur J Heart Fail. 2021;23:844-845.
    PubMed        

  36. BAYES-GENIS A
    The CONCERT-HF trial: a sweet and sour symphony.
    Eur J Heart Fail. 2021;23:675-676.
    PubMed        

  37. BISSON A, Ding WY, Bodin A, Lip GYH, et al
    Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation with heart failure.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2292.
    PubMed        

  38. BAYES-GENIS A, Januzzi JL, Richards AM, Arfsten H, et al
    The "Peptide for Life" Initiative: A Call for Action to Provide Equal Access for the Use of Natriuretic Peptides in the Diagnosis of Acute Heart Failure across Europe.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2293.
    PubMed        

  39. KRESOJA KP, Rommel KP, Wachter R, Henger S, et al
    Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction.
    Eur J Heart Fail. 2021 Jul 7. doi: 10.1002/ejhf.2291.
    PubMed         Abstract available

  40. NUNEZ J, de la Espriella R, Minana G, Santas E, et al
    Antigen Carbohydrate 125 as a Biomarker in Heart Failure: a Narrative Review.
    Eur J Heart Fail. 2021 Jul 9. doi: 10.1002/ejhf.2295.
    PubMed         Abstract available

  41. GARCIA-PAVIA P, Rapezzi C, Adler Y, Arad M, et al
    Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.
    Eur J Heart Fail. 2021;23:512-526.
    PubMed         Abstract available

  42. STRANGE G, Playford D, Scalia GM, Celermajer DS, et al
    Change in ejection fraction and long-term mortality in adults referred for echocardiography.
    Eur J Heart Fail. 2021;23:555-563.
    PubMed         Abstract available

  43. COATS AJS, Rosano G
    Treatments delayed lead to lives lost.
    Eur J Heart Fail. 2021;23:511.
    PubMed        

  44. VEENIS JF, Brugts JJ, Yalcin YC, Caliskan K, et al
    Reply to 'Aortic valve surgery and left ventricular assist device: lights and shadows'.
    Eur J Heart Fail. 2021;23:842-843.
    PubMed        

  45. ARNOLD SV, Butler J, Spertus JA
    Standardizing the standard: reporting health status in clinical trials.
    Eur J Heart Fail. 2021;23:203-204.
    PubMed        

  46. KHEDRAKI R, Tang WHW
    Identifying sodium non-excretors: heart failure's emerging golden ticket for risk stratification.
    Eur J Heart Fail. 2021;23:740-742.
    PubMed        

  47. SUGUMAR H, Nanayakkara S, Vizi D, Wright L, et al
    A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF.
    Eur J Heart Fail. 2021;23:785-796.
    PubMed         Abstract available

  48. OLSEN FJ, Solomon SD, Biering-Sorensen T
    Piecing together the puzzle of sex-specific differences in left ventricular ejection fraction.
    Eur J Heart Fail. 2021;23:417-419.
    PubMed        

  49. BRAUNWALD E, Antman EM
    The path to universality.
    Eur J Heart Fail. 2021;23:381-383.
    PubMed        

  50. TOMASONI D, Coats AJS
    The Altmetric Attention Score: how science tries to meet social media.
    Eur J Heart Fail. 2021;23:693-697.
    PubMed        

  51. DOCHERTY KF, Curtain JP, Anand IS, Bengtsson O, et al
    Effect of dapagliflozin on anaemia in DAPA-HF.
    Eur J Heart Fail. 2021;23:617-628.
    PubMed         Abstract available

  52. STOGIOS N, Fezza G, Wong JV, Ross HJ, et al
    Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.
    Eur J Heart Fail. 2021;23:205-207.
    PubMed        


    Hypertension

  53. KARIO K, Williams B
    Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments.
    Hypertension. 2021 Jul 6:HYPERTENSIONAHA12117440.
    PubMed         Abstract available


    J Card Fail

  54. MENTZ RJ, Mulder H, Mosterd A, Sweitzer NK, et al
    Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
    J Card Fail. 2021 Jun 24. pii: S1071-9164(21)00206.
    PubMed         Abstract available


    J Cardiovasc Pharmacol

  55. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
    Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
    J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
    PubMed        


    J Thorac Cardiovasc Surg

  56. LEE SH, Choi KH, Song YB, Jeong DS, et al
    Comprehensive assessment of heart failure in patients with preserved ejection fraction undergoing coronary bypass grafting.
    J Thorac Cardiovasc Surg. 2021 Jun 19. pii: S0022-5223(21)00980.
    PubMed         Abstract available


    PLoS One

  57. GOLAND S, Volodarsky I, Fabricant Y, Livschitz S, et al
    Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.
    PLoS One. 2021;16:e0254104.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: